Skip to main content

Table 1 Composition of rosuvastatin chitosomes nanoparticles formulations and the obtained values for the studied responses

From: Development of rosuvastatin flexible lipid-based nanoparticles: promising nanocarriers for improving intestinal cells cytotoxicity

RunX1
(MR)
X2
(%)
X3
(%)
Y1Y2
(%)
Y3
(mV)
Size (nm)PDI
11.00.010.4239.48 ± 5.330.344 ± 0.06590.88 ± 1.6512.66 ± 1.58
24.00.040.4225.27 ± 6.590.425 ± 0.09586.94 ± 4.9418.10 ± 3.38
32.50.040.2112.19 ± 2.900.288 ± 0.00985.14 ± 5.04− 1.83 ± 0.55
42.50.010.6554.33 ± 11.060.573 ± 0.04594.59 ± 1.6226.74 ± 0.26
52.50.040.6507.40 ± 18.140.581 ± 0.05191.97 ± 4.8926.07 ± 1.90
64.00.010.4295.40 ± 5.110.258 ± 0.02388.75 ± 3.9910.70 ± 0.16
74.00.0250.6547.33 ± 20.090.511 ± 0.02492.79 ± 1.7628.87 ± 1.39
82.50.010.2163.13 ± 3.290.391 ± 0.05387.94 ± 2.04− 8.14 ± 0.51
91.00.0250.6535.33 ± 43.120.543 ± 0.05393.22 ± 1.2427.23 ± 0.31
101.00.0250.2132.77 ± 4.460.439 ± 0.06187.61 ± 2.07−10.07 ± 1.26
111.00.040.4219.53 ± 6.360.354 ± 0.07190.63 ± 2.1513.15 ± 0.75
124.00.0250.2132.97 ± 2.110.318 ± 0.02284.78 ± 3.09−6.92 ± 0.16
132.50.0250.4255.83 ± 8.370.394 ± 0.12885.44 ± 2.2111.26 ± 2.04
142.50.0250.4252.30 ± 3.840.318 ± 0.08886.38 ± 3.0311.83 ± 2.67
152.50.0250.4259.77 ± 3.690.382 ± 0.04385.15 ± 4.0714.87 ± 1.89
  1. Abbreviations: X1 Drug to phospholipid, X2 Surfactant concentration, X3 Coating solution concentration, Y1 Particle size (nm,Y2 Entrapment efficiency (%), Y3 Zeta potential (mV), MR Molar ratio, PDI Poly dispersity index